Clinical Trial Update: A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Ubamatamab with and without REGN7075 in adults with advanced or metastatic non-small cell lung cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• REGN7075 (REGN7075)
• Ubamatamab (ubamatamab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING